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A B S T R A C T
Objective: Velopharyngeal hypotonia seems to be an important factor in velopharyngeal dysfunction in
22q11.2 deletion syndrome, but the etiology is not understood. Because TBX1 maps within the typical
22q11.2 deletion and Tbx1-deﬁcient mice phenocopy many ﬁndings in patients with the 22q11.2
deletion syndrome, TBX1 is considered the major candidate gene in the etiology of these defects. Tbx1
heterozygosity in mice results in abnormal vocalization 7 days postnatally, suggestive of velopharyngeal
dysfunction. Previous case–control studies on muscle specimens from patients and mice revealed no
evidence for a myogenic cause of velopharyngeal dysfunction. Velopharyngeal muscles are innervated
by cranial nerves that receive signals from the nucleus ambiguus in the brainstem. In this study, a
possible neurogenic cause underlying velopharyngeal dysfunction in Tbx1 heterozygous mice was
explored by determining the size of the nucleus ambiguus in Tbx1 heterozygous and wild type mice.
Methods: The cranial motor nuclei in the brainstems of postnatal day 7 wild type (n = 4) and Tbx1
heterozygous (n = 4) mice were visualized by in situ hybridization on transverse sections to detect Islet-1
mRNA, a transcription factor known to be expressed in motor neurons. The volumes of the nucleus
ambiguus were calculated.
Results: No substantial histological differences were noted between the nucleus ambiguus of the two
groups. Tbx1 mutant mice had mean nucleus ambiguus volumes of 4.6 million mm3 (standard error of the
mean 0.9 million mm3) and wild type mice had mean volumes of 3.4 million mm3 (standard error of the
mean 0.6 million mm3). Neither the difference nor the variance between the means were statistically
signiﬁcant (t-test p = 0.30, Levene’s test p = 0.47, respectively).
Conclusions: Based on the histology, there is no difference or variability between the volumes of the
nucleus ambiguus of Tbx1 heterozygous and wild type mice. The etiology of velopharyngeal hypotonia
and variable speech in children with 22q11.2 deletion syndrome warrants further investigation.
 2013 Elsevier Ireland Ltd. All rights reserved.
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The 22q11.2 deletion syndrome (22q11DS) is the most frequent
survivable human syndrome that is caused by a hemizygous
microdeletion within a chromosome [1]. In approximately 85% of
all 22q11DS patients, a 3 megabase (Mb) region on chromosome 22
is deleted [2] containing about 45 genes [3]. One of the genes that
maps within the deleted region is Tbx1, which is expressed in
pharyngeal endodermal pouches, in pharyngeal mesoderm includ-
ing the mesodermal cores of the pharyngeal arches, and in head
mesenchyme during embryonic development [1] and in the brain
after birth [4]. Major phenotypes of 22q11DS can be related to§ Presented at the Symposium for Experimental Research in Surgical Specialties
(November 2012, Amsterdam, The Netherlands).
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http://dx.doi.org/10.1016/j.ijporl.2013.03.032aberrant development of the pharyngeal arches and pouches 3, 4,
and 6, including facial dysmorphism, feeding and speech problems
due to velopharyngeal dysfunction (VPD), hypocalcaemia due to
parathyroid dysfunction, immune disorders due to thymus
dysfunction, and congenital heart disease.
VPD occurs when the valve mechanism of the soft palate and the
lateral and posterior pharyngeal walls fail to close the port between
the oral and nasal cavities, resulting in hypernasal speech. Some
children with VPD undergo surgery to decrease the size of the
velopharyngeal port. In general, postoperative residual VPD is more
prevalent among children with 22q11DS than in children without
the syndrome [5–11], but some patients with 22q11DS fare as well
as their non-syndromic counterparts [12–17]. It is not clear why
some children with 22q11DS beneﬁt more from surgery than others
[7,18]. Phenotype variability of VPD in 22q11DS has been one of the
research foci of the 22q11DS team at our tertiary hospital.
All surgical techniques rely on some intrinsic muscle activity for
closure of the remaining velopharyngeal port [19]. A possible
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neuromuscular component of VPD in 22q11DS as seen on
nasendoscopic views of attempted velopharyngeal closure [20].
On magnetic resonance imaging, the pharyngeal constrictor
muscle in patients with 22q11DS was found to be hypotrophic
compared to controls [21], which may be the result of abnormal
development of the muscle or its innervation. The etiology of
velopharyngeal hypotonia is uncertain, but may primarily result
from myogenic or neurogenic abnormalities. Superior constrictor
muscle biopsies taken from children with and without 22q11DS
revealed no clear histological differences, suggesting a nonmyo-
genic origin of velopharyngeal hypotonia in patients with 22q11DS
[22]. Whether a neurogenic cause underlies VPD in patients with
22q11DS is unclear.
Neurogenic pharyngeal weakness is seen in amyotrophic lateral
sclerosis, a neurodegenerative disease accompanied by a de-
creased number of cells in the brainstem nucleus ambiguus (nA)
[23,24]. The nA transmits signals from the cerebral cortex to the
vagal (n.X) and accessory (n.XI) cranial nerves which innervate the
pharyngeal muscles [25–27]. Additionally, some patients with
Mo¨bius syndrome, which is characterized by congenital weakness
or paralysis of the muscles innervated by the facial nerve (n.VII),
have hypoplastic brainstem facial cranial nerve nuclei with fewer
neurons than controls [28–30]. Similarly, congenital VPD in
22q11DS could be caused by hypoplastic development of the
nA. Unfortunately, noninvasive imaging does not permit an
accurate estimation of the size the brainstem nuclei [31],
necessitating a histological analysis of brainstem tissue.
Postmortem human brainstem material is difﬁcult to obtain,
therefore we resorted to studying an animal model of 22q11DS.
Among vertebrate model organisms, the neuronal architecture of
the mouse is the most similar to that of humans [32]. Mouse
models for 22q11DS have been generated by deleting a 1 Mb
homologous region on mouse chromosome 16 (Df(16)1, LgDel)
including Tbx1, or speciﬁcally disrupting the Tbx1 gene [33,34]. The
phenotype of Tbx1 heterozygous mutant mice (Tbx1+/) is less
penetrant and does not phenocopy the entire phenotypic spectrum
of patients with 22q11DS. However, recent ﬁndings demonstrated
that seven to eight-day-old Tbx1+/ mouse pups (P7–8) may have
VPD since they vocalize at a lower frequency and for a shorter
duration compared to wild type littermates [35]. Interestingly, a
loss-of-function point-mutation of TBX1 in patients without the
typical 22q11.2 deletion, results in phenotypes similar to those
found in patients with 22q11DS, including VPD [36]. Therefore,
Tbx1+/ mice can be used as an adequate model to study the VPD
phenotype found in 22q11DS.
Moreover, as in patients with 22q11DS, phenotypic variance is
seen in the Tbx1+/ mouse model [37]: all Tbx1+/ embryos have
fourth pharyngeal arch artery hypoplasia at E10.5, but at term only
30–50% have fourth pharyngeal arch artery-derived cardiovascular
defects [33]. The differences in phenotypic penetrance depends on
the genetic background of the mouse strains [37–39], and on
genetic modiﬁers including Vegfa, Nrp1, Spry, and retinoic acid [40–
44].
The presence of velopharyngeal hypotonia as underlying cause
for the VPD was not speciﬁcally mentioned in the study with
mouse pups [35] nor in the study with patients with the TBX1
point-mutation [36]. The requirement of Tbx1 during development
of velopharyngeal muscles and nerves has been shown in Tbx1-
deﬁcient (Tbx1/) mice which die during fetal and neonatal
stages: Tbx1/ mice have hypoplastic branchiomeric head and
neck muscles [45,46] and abnormally fused ganglia of the
glossopharyngeal (n.IX) and n.X nerves [47,48]. Thus, although
Tbx1 is not expressed in primary neural crest cells [49], the neural
crest-derived ganglia are aberrantly formed in the absence of Tbx1
[50].The objective of this study was to explore the possibility that a
neurogenic defect causes velopharyngeal hypotonia in 22q11DS by
comparing the gross histology of the nA in the Tbx1+/ mouse
model for 22q11DS to that of wild type mice. Diminished or absent
activity of Tbx1 gene may indirectly effect the brainstem as it does
the cranial nerves [47,48]. Our results indicate that the volume of
the nA is not signiﬁcantly affected by Tbx1 haplosufﬁciency.
2. Materials and methods
2.1. Mice
Tbx1+/lacZmice [33] were intercrossed to generate wild type and
heterozygous mutant pups. Genotypes were conﬁrmed by PCR
using primers speciﬁc for the lacZ gene [33]. All mice were
maintained on an FVB background. Animal care was in accordance
with national and institutional guidelines. The experimental
procedure was approved by the animal ethics committee of the
Academic Medical Center in Amsterdam, the Netherlands. On
postnatal day 7 (P7) the pups (n = 4 of each genotype) were
brought into a hypercapnic coma in a sealed cage and sacriﬁced for
tissue isolation. The brainstems were isolated in ice-cold
phosphate-buffered saline (PBS 1x), ﬁxed by overnight immersion
in 4% paraformaldehyde (PFA), and embedded in paraplast for
further processing.
2.2. In situ hybridization
Embedded brainstem tissue was cut into 10 mm thick
transverse sections with a Leica RM 2165 rotation microtome,
mounted on Starfrost slides, and processed for non-radioactive in
situ hybridization (ISH) as described [51]. The brainstem motor
nuclei were visualized by ISH with a DIG-labeled Islet-1 (Isl1)
[52,53] mRNA probe [51]. The sections were photographed using a
camera connected to a Zeiss Axiophot microscope.
2.3. Outcome
Morphometric analyses were performed blinded using imaging
software (Amira 5.4, Visage Imaging, San Diego, CA, USA). The nA of
the mutant and the wild type pups were compared qualitatively by
describing the appearance, and quantitatively by calculating the
volume marked by Isl1. Rather than measuring every section that
contained the nA, the surface area of the nA on a minimum of 10
equally spaced sections encompassing the nA were measured.
Using Cavalieri’s principle, the sum of the measured areas was
multiplied by the distance between the selected sections (Fig. 1).
This approximation of the volume is accurate to within 5% of the
true volume [54]. The volumes of the nA of Tbx1+/ and wild type
mice were compared using a two-tailed t-test. The variance was
measured with Levene’s test. Statistical calculations were per-
formed using IBM SPSS Statistics for Windows (Version 20.0.
Armonk, NY, USA).
2.4. Sample size calculation
The number of pups needed to obtain statistically signiﬁcant
results, was determined based on a study in which n.X innervation
of the stomach was compared between wild type and Tbx1+/mice
[48]. At embryonic day 16.5 (E16.5), signiﬁcantly less n.X ﬁbers
intersected in the stomachs of Tbx1+/ mice (n = 9) than in wild
type mice (n = 9) (14.6  1.6 vs. 20.4  1.3, p < 0.05). With these
numbers, the required sample size to ﬁnd a similarly signiﬁcant
difference in nA volumes between the genotypes, with an alpha of
0.05, and a power of 0.80 is only n = 2 pups per genotype. Since this
calculation is based on the n.X and not the nA, this number was
Fig. 1. Methods. Sagittal view of a mouse brain and brainstem showing the locations of the facial nucleus (nVII) and nucleus ambiguus (nA). Signals from the cerebral motor
cortex are relayed to the velopharyngeal muscles via the nA. Inset showing magniﬁcation and Cavalieri’s principle of calculating the volume of a structure based on equally
spaced transverse sections.
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study.
3. Results
To test whether a neurogenic abnormality underlies velophar-
yngeal hypotonia in patients with 22q11DS, we harvested and
analyzed brainstems from Tbx1+/ (n = 4) and wild type (n = 4)
pups from two litters. No macroscopic qualitative differences were
noted between both genotypes. As previously described [55–57],
the spindle-shaped nA extends cranio-caudally from the facial
nucleus (nVII) to the pyramidal decussation [58]. To identify and
localize the nA (Fig. 2A), we used a riboprobe directed against Isl1
mRNA, encoding a LIM domain-containing transcription factor. Isl1
is expressed in motor neurons of all cranial nerves, including the
oculomotor, trochlear, trigeminal, abducens, facial, ambiguus, and
hypoglossal nuclei in the brainstem [52,59,60]. This approach
furthermore allowed the identiﬁcation of the facial nucleus
directly cranial to the nA and the hypoglossal nucleus dorsal to
the nA [61], facilitating the localization of the nA. We found that
within the nA, the cranially located neurons are packed more
compactly and the caudally located neurons are more loosely
arranged (Fig. 2B). The nA in the two genotype groups did not differ
in shape or cell density. Quantitatively, Tbx1+/ mutant pups had
mean nucleus ambiguus volumes of 4.6 million mm3 (standard
error of the mean (SEM) 0.9 million mm3) and wild type mice had
mean volumes of 3.4 million mm3 (SEM 0.6 million mm3) (Fig. 2C).
The difference between the means was not statistically signiﬁcant
(t-test p = 0.30), nor was the variance (Levene’s test p = 0.47).Fig. 2. Nucleus ambiguus of Tbx1+/ and wild type P7 pups. (A) Isl1 in situ hybridization-la
ambiguus, showing cranial compact and caudal loosely spread cells. (C) Mean volumes 
cube = 1 million mm3.4. Discussion
Velopharyngeal hypotonia is a common cause of VPD in
patients with 22q11DS. However, the etiology and subsequent
speech problems in children with 22q11DS is still poorly
understood. We previously demonstrated that myogenic distur-
bances did not seem to underlie VPD in 22q11DS children [22]. In
this study, we aimed to determine whether a neurogenic cause
underlies velopharyngeal hypotonia. The size of the nA is
decreased in other diseases with velopharyngeal hypotonia
[23,24,28–30]. We measured the volume of the nA in mice
heterozygous for Tbx1, the major candidate gene in the etiology of
22q11DS, and did not observe a clear difference or variability in the
volumes of the nA compared with wild type mice.
4.1. Evidence of neurologic deﬁcits in Tbx1 mouse mutants and
22q11DS human patients
The lack of difference in nA volumes between the genotypes
does not disprove a neurologic etiology of the supposed VPD in
Tbx1+/ mice. Cerebral deﬁcits are apparent in Tbx1+/ mice:
relative to wild type mice, they have reduced prepulse inhibition
[4], lower grip strength, and delayed movement initiation [62]. The
defects seem to be subtle: even in the LgDel model, adult mouse
brains show no signiﬁcant changes in weight or gross morphologi-
cal appearance [63]. Tbx1 expression is limited to the brain
vasculature, suggesting that microvascular abnormalities contrib-
ute to the phenotypes found in these mutants [4]. Distal to the nA,
the morphology and volumes of the n.X ganglia do not differ
between Tbx1+/ and wild type mouse embryos, but a signiﬁcantbeled transverse brainstem sections. Scale: bar = 1 mm. (B) Magniﬁcation of nucleus
of the nucleus ambiguus. Error bars = standard error of the mean. Scale: small dark
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observed in Tbx1+/ mutants compared to wild type mouse
embryos, suggesting defective n.X projections [48]. Pharyngeal
projections have not been studied beyond embryonic day 10 thus
far [47].
Clinically, impaired n.X function as evidenced by velar paresis
(n = 10/13) [64], as well as velar and pharyngeal motion are
negatively affected in 22q11DS patients compared to nonsyn-
dromic patients with a repaired cleft palate [65,66]. Moreover,
dysfunction of the muscles normally innervated by the nA in
22q11DS are suggested to cause polyhydramnios [67,68] due to
swallowing disorders [69], a hoarse voice [5,70–75] presumably
due to laryngeal muscle hypotonia [76,77], and case reports of
aspiration [68,78,79]. These phenotypic characteristics could
result from neurogenic or myogenic abnormalities.
The neurogenic component of the syndrome needs attention. In
some patients with 22q11DS the velopharyngeal valve mechanism
is sufﬁcient during swallowing, but not during speech. The nA
relays motor signals to the velopharynx as well as to the intrinsic
muscles of the larynx and the upper esophagus. The nA is active
during vocalization, respiration, sneezing, coughing, swallowing,
and the gag reﬂex [25]. In all motor neurons that are related to both
swallowing and vocalization, higher electromyographic (EMG)
activity levels were achieved during swallowing, reﬂecting that
more forceful adduction of the vocal folds is needed for glottal
closure during swallowing to protect the airway against aspiration
[80]. If the muscles can be sufﬁciently forcefully activated during
reﬂexive swallowing in 22q11DS, hypotonia during speech may
indicate impairment of the cerebral voluntary component of
vocalization.
4.2. Limitations of this study
The Tbx1 mouse background used in this study (FVB) differs
from that used in the vocalization study (C57BL/6J) [35], which
could affect the penetrance of defects [37,38], because an FVB
genetic background offers a protective effect with regard to fourth
pharyngeal arch artery development [39]. Therefore, an FVB
background could also be protective with regard to nA develop-
ment and VPD. Additionally, the phenotypic variability of 22q11DS
may reﬂect the array of genetic variability in humans which could
not be recapitulated in experimental animals with a homogeneous
background [45].
Another important limitation of this study is that only the
histology of the nA has been studied by labeling Isl1. No evidence
has been presented that could prove normal function. During
embryology and postnatal growth, morphology and physiological
function are not necessarily temporally coincident [81]; abnor-
malities may be apparent on electrophysiological examination
without histopathological abnormalities [32].
Finally, in 22q11DS typically around 45 genes are deleted.
Although the lower frequency and decreased duration of
vocalization in Tbx1+/ mutants suggests that this gene may
primarily contribute to VPD, other genes could function in parallel
or in the same genetic pathway [46]. Other candidate genes in the
deleted region include CLTD which is expressed in skeletal muscle,
its deletion may contribute to hypotonia [82]; CRKL which is
expressed in migrating neural crest cells; its deletion results in
hypoplastic n.IX and n.X [83]; and Cdcrel-1(Pnut1) which is
expressed in the n.IX and n.X [84]. Haplosufﬁciency of six other
genes (Slc25a1, Prodh, Mrpl40, aZdhhc8, Txnrd2, and T10) deleted in
the syndrome might negatively affect synaptogenesis which peaks
at P0 [63]. Haplosufﬁciency of three other genes (DGCR6(L) and
PRODH) may contribute to neurochemical imbalance in the
excitatory and inhibitory neurotransmitters GABA and glutamate
[85,86].4.3. Future studies
To further differentiate between a neurogenic and myogenic
etiology of velopharyngeal hypotonia in 22q11DS, an invasive
neuromuscular conduction study (EMG) of the velopharyngeal
muscles could be performed [87]. Electrophysiological analysis in
distinct regions of the brain in wild type and Tbx1 heterozygous
mice should shed light on the contribution of the cerebral cortex to
velopharyngeal closure [63].
5. Conclusions
This study is a step in the process of unraveling the hitherto
inadequately explained variation between genotype and pheno-
type in 22q11DS [37]. The phenotypes among patients with
22q11DS vary greatly [3,37]. Parents and caretakers of children
with 22q11DS are left with many questions about the likely
manifestations and the course of these problems in time. Mice
deﬁcient for Tbx1 are known to display a variety of abnormalities
similar to those described in 22q11DS, but the mutation does not
seem to affect the morphology or volume of the nA since there
were no differences between Tbx1 heterozygous and wild type
mice. The volumes did not vary more within the mutant group than
in the wild type group. The underlying cause of velopharyngeal
hypotonia and subsequent speech problems in children with
22q11DS continues to be unknown. It is likely that genetic
modiﬁers beyond the 22q11DS genes play a key role in
determining 22q11DS phenotypic severity [63]. With increasing
knowledge, the parents and caretakers of children with 22q11DS
can be better informed about the expected outcome after
velopharyngeal surgery for VPD. Finally, improving our under-
standing the underlying mechanisms that cause VPD in 22q11DS
may lead to novel therapeutic and/or diagnostic methods.
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